X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (34) 34
oncology (31) 31
index medicus (30) 30
female (24) 24
male (22) 22
middle aged (21) 21
adult (20) 20
chemotherapy (19) 19
treatment outcome (19) 19
hematology, oncology and palliative medicine (17) 17
sarcoma (17) 17
aged (16) 16
cancer (15) 15
disease-free survival (13) 13
tumors (13) 13
young adult (12) 12
adolescent (11) 11
clinical trials (11) 11
follow-up studies (11) 11
care and treatment (10) 10
ifosfamide (10) 10
imatinib mesylate (10) 10
metastasis (10) 10
neoplasm staging (10) 10
antineoplastic agents - therapeutic use (8) 8
cancer therapies (8) 8
combined modality therapy (8) 8
sarcoma - drug therapy (8) 8
survival (8) 8
aged, 80 and over (7) 7
analysis (7) 7
antineoplastic agents - adverse effects (7) 7
disease progression (7) 7
docetaxel (7) 7
gemcitabine (7) 7
patients (7) 7
soft tissue neoplasms - drug therapy (7) 7
therapy (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
drug administration schedule (6) 6
incidence (6) 6
prognosis (6) 6
risk assessment (6) 6
sarcoma - pathology (6) 6
sarcoma - therapy (6) 6
solid tumors (6) 6
studies (6) 6
survival rate (6) 6
trial (6) 6
abridged index medicus (5) 5
adjuvant chemotherapy (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
dose imatinib (5) 5
drug therapy (5) 5
europe - epidemiology (5) 5
gastrointestinal stromal tumors - pathology (5) 5
gist (5) 5
ifosfamide - administration & dosage (5) 5
kaplan-meier estimate (5) 5
mutation (5) 5
pyrimidines - therapeutic use (5) 5
sarcoma - mortality (5) 5
soft tissue neoplasms - pathology (5) 5
surgery (5) 5
survival analysis (5) 5
antineoplastic agents - administration & dosage (4) 4
bone neoplasms - drug therapy (4) 4
chemotherapy, adjuvant (4) 4
child (4) 4
diagnosis (4) 4
double-blind method (4) 4
doxorubicin - administration & dosage (4) 4
efficacy (4) 4
european-organization (4) 4
france (4) 4
gastrointestinal stromal tumors - diagnosis (4) 4
gastrointestinal stromal tumors - drug therapy (4) 4
infusions, intravenous (4) 4
kinase (4) 4
kit (4) 4
medicine, general & internal (4) 4
pazopanib (4) 4
product development (4) 4
radiotherapy (4) 4
sarcoma - diagnosis (4) 4
soft tissue neoplasms - mortality (4) 4
time factors (4) 4
[ sdv.can ] life sciences [q-bio]/cancer (3) 3
adjuvant imatinib (3) 3
anthracyclines (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
biopsy (3) 3
cytotoxicity (3) 3
dacarbazine (3) 3
disease (3) 3
doxorubicin (3) 3
drug dosages (3) 3
ecteinascidin-743 (3) 3
gastrointestinal stromal tumors (3) 3
gastrointestinal stromal tumors - therapy (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 415 - 423
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10028, pp. 1629 - 1637
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1879 - 1886
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 6, pp. 561 - 570
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
Summary Background Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 9, pp. 1261 - 1271
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 949 - 956
Summary Background Diffuse-type tenosynovial giant cell tumour (dt-GCT) of the soft tissue (alternatively known as pigmented villonodular synovitis), an orphan... 
Hematology, Oncology and Palliative Medicine | PIGMENTED VILLONODULAR SYNOVITIS | DIAGNOSIS | THERAPY | EFFICACY | ONCOLOGY | PERIORBITAL EDEMA SECONDARY | MACROPHAGES | RECEPTOR | ANTIBODY | ARTHRITIS | IMATINIB MESYLATE | Receptor, Macrophage Colony-Stimulating Factor - antagonists & inhibitors | Receptor, Macrophage Colony-Stimulating Factor - immunology | Giant Cell Tumors - immunology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Giant Cell Tumors - pathology | Soft Tissue Neoplasms - drug therapy | Male | Antineoplastic Agents - administration & dosage | Giant Cell Tumors - metabolism | Receptor, Macrophage Colony-Stimulating Factor - metabolism | Synovitis, Pigmented Villonodular - drug therapy | Synovitis, Pigmented Villonodular - pathology | Soft Tissue Neoplasms - immunology | Young Adult | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Drug Administration Schedule | Soft Tissue Neoplasms - metabolism | Synovitis, Pigmented Villonodular - metabolism | Treatment Outcome | Synovitis, Pigmented Villonodular - immunology | Giant Cell Tumors - drug therapy | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Infusions, Intravenous | Monoclonal antibodies | Macrophage colony stimulating factor | Tumors
Journal Article